The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
In the citing paper
“both the rarity of co-drivers and strong addiction to the ALK fusion oncoprotein may account for the long progression-free survival observed in patients with ALK-rearrangements with the potent and selective second and third generation ALK inhibitors alectinib, brigatinib and lorlatinib23, 26, 27.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationOu, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citationALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
- Lu S, 2016, J Clin Oncol
- Hida T, Lancet
Cited by
Sorted by citations
Items 201–300 of 1,000
The evolving landscape of sex-based differences in lung cancer: a distinct disease in women
Ragavan, M. V., & Patel, M. I. (2022) · European Respiratory Review · doi:10.1183/16000617.0100-2021 · Cited by 88
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 94
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Prokoph, N., Larose, H., Lim, M. S., Burke, G. A. A., & Turner, S. D. (2018) · Cancers · doi:10.3390/cancers10040099 · Cited by 87
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Huang, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113448 · Cited by 89
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis
Tehranian, C., Fankhauser, L., Harter, P. N., Ratcliffe, C. D. H., Zeiner, P. S., Messmer, J. M., Hoffmann, D. C., Frey, K., Westphal, D., Ronellenfitsch, M. W., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab159 · Cited by 87
Drilon, A. E. D. C., Duruisseaux, M., Han, J., Ito, M., Falcon, C. J., Yang, S., Murciano‐Goroff, Y. R., Chen, H., Okada, M., Molina‐Vila, M. Á., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03307 · Cited by 88
Self-citationSun, N., Ren, C., Kong, Y., Zhong, H., Chen, J., Li, Y., Zhang, J., Zhou, Y., Qiu, X., Lin, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112190 · Cited by 85
Mahajan, P., Casanova, M., Ferrari, A., Fordham, A. M., Trahair, T. N., & Venkatramani, R. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100768 · Cited by 85
Yang, J. C., Ou, S. I., Petris, L. D., Gadgeel, S. M., Gandhi, L., Kim, D., Barlési, F., Govindan, R., Dingemans, A. C., Crinò, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.070 · Cited by 85
Self-citationLetovanec, I., Finn, S. P., Zygoura, P., Smyth, P. C., Soltermann, A., Bubendorf, L., Speel, E. M., Marchetti, A., Nonaka, D., Monkhorst, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.117 · Cited by 84
Self-citationBrigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Lin, J. J., Zhu, V. W., Schoenfeld, A. J., Yeap, B. Y., Saxena, A., Ferris, L. A., Dagogo‐Jack, I., Farago, A. F., Taber, A. M., Traynor, A. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.005 · Cited by 84
Self-citationALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
Zhang, Q., Xiao, M., Gu, S., Xu, Y., Liu, T., Li, H., Yu, Y., Qin, L. F., Zhu, Y., Chen, F., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0264-3 · Cited by 83
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remón, J., Ahn, M., Girard, N., Johnson, M. L., Kim, D., Lopes, G. D. L., Jr., Pillai, R. N., Solomon, B., Villacampa, G. J., & Zhou, Q. H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.022 · Cited by 84
Self-citationBrain metastases in oncogene-driven non-small cell lung cancer
Nishino, M., Soejima, K., & Mitsudomi, T. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.15 · Cited by 84
Bander, E. D., Yuan, M., Carnevale, J. A., Reiner, A. S., Panageas, K. S., Postow, M. A., Tabar, V. S., & Moss, N. S. (2021) · Cancer · doi:10.1002/cncr.33459 · Cited by 86
Waliany, S., Zhu, H., Wakelee, H. A., Padda, S. K., Das, M. S., Ramchandran, K. J., Myall, N. J., Chen, T., Witteles, R. M., & Neal, J. W. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.030 · Cited by 83
Wang, Y., Han, L., Liu, F., Yang, F., Jiang, X., Sun, H., Feng, F., Xue, J., & Liu, W. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110795 · Cited by 82
Clinical implications of food–drug interactions with small-molecule kinase inhibitors
Veerman, G., Hussaarts, K. G. A. M., Jansman, F. G. A., Koolen, S. L. W., van Leeuwen, R. W. F., & Mathijssen, R. H. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30069-3 · Cited by 83
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 83
Evolving trends in lung cancer
Deshpand, R., Chandra, M., & Rauthan, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_52_21 · Cited by 86
Petrek, H. E., & Yu, A. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.528 · Cited by 82
Pillai, R. N., Fennell, D. A., Kovčin, V., Ciuleanu, T., Ramlau, R., Kowalski, D. M., Schenker, M., Yalcin, I., Teofilovici, F., Vukovic, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00816 · Cited by 81
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 85
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Xie, S., Sun, Y., Liu, Y., Li, X., Li, X., Zhong, W., Zhan, F., Zhu, J., Yao, H., Yang, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00270 · Cited by 81
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
Seegobin, K., Majeed, U., Wiest, N. E., Manochakian, R., Lou, Y., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750657 · Cited by 83
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
Elliott, J., Bai, Z., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., Yousef, S., Zheng, C., Stewart, D. J., & Wells, G. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229179 · Cited by 81
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, W., Franchini, F., Alexander, M., Officer, A., Wong, H., IJzerman, M. J., Desai, J., & Solomon, B. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.030 · Cited by 80
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Rivera‐Concepción, J., Uprety, D., & Adjei, A. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.078 · Cited by 84
Shiba‐Ishii, A., Johnson, T. W., Dagogo‐Jack, I., Mino-Kenudson, M. A., Johnson, T. R., Wei, P. Y., Weinrich, S. L., McTigue, M. A., Walcott, M., Nguyen-Phuong, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00399-6 · Cited by 80
Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., Sakamoto, T., Murakami, H., Kishimoto, J., Matsumoto, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.021 · Cited by 81
Choudhuri, S. P., Girard, L., Lim, J. Y. S., Wise, J. F., Freitas, B., Yang, D., Wong, E., Hamilton, S., Chien, V. D., Kim, Y. J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0656 · Cited by 78
Lévy, A., Finn, C. F., Hasan, B., Maio, E. D., Berghoff, A. S., Girard, N., Greillier, L., Lantuéjoul, S., O'Brien, M. E. R., Reck, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.067 · Cited by 81
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 80
Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Funazo, T. Y., Furugaki, K., Yoshimura, Y., Yamazoe, M., Ajimizu, H., Yasuda, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13771-5 · Cited by 79
Özdemir, B. C., Gerard, C. L., & da Silva, C. E. (2022) · Endocrinology · doi:10.1210/endocr/bqac058 · Cited by 83
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
Rheinheimer, S., Heußel, C. P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., Herth, F. J. F., Muley, T., Liersch, S., Bischoff, H. G., et al. (2020) · Cancers · doi:10.3390/cancers12041046 · Cited by 77
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 80
Lin, J. J., Schoenfeld, A. J., Zhu, V. W., Yeap, B. Y., Chin, E. N., Rooney, M. M., Plodkowski, A. J., Digumarthy, S. R., Dagogo‐Jack, I., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.014 · Cited by 78
Self-citationRemón, J., Pignataro, D., Novello, S., & Passiglia, F. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102178 · Cited by 77
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 76
Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review
Balzer, B. W. R., Loo, C. K. C., Lewis, C. R., Trahair, T. N., & Anazodo, A. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2020 · Cited by 75
Brain metastases: An update on the multi-disciplinary approach of clinical management
Mitchell, D. K., Kwon, J. H., Kubica, P. A., Huff, W. X., O'Regan, R. M., & Dey, M. (2021) · Neurochirurgie · doi:10.1016/j.neuchi.2021.04.001 · Cited by 79
Wei, Z., Yang, X., Ye, X., Feng, Q., Xu, Y., Zhang, L., Sun, W., Dong, Y., Qi, M., Li, T., et al. (2020) · European Radiology · doi:10.1007/s00330-019-06613-x · Cited by 75
“How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
LeBlanc, T. W., Temel, J. S., & Helft, P. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201211 · Cited by 74
Targeting anaplastic lymphoma kinase in neuroblastoma
Umapathy, G., Mendoza-García, P., Hallberg, B., & Palmer, R. H. (2019) · Apmis · doi:10.1111/apm.12940 · Cited by 74
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
Gristina, V., Mantia, M. L., Iacono, F., Galvano, A., Russo, A. D., & Bazan, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120474 · Cited by 73
Sakata, S., Otsubo, K., Yoshida, H., Ito, K., Nakamura, A., Teraoka, S., Matsumoto, N., Shiraishi, Y., Haratani, K., Tamiya, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15176 · Cited by 73
Molecular Imaging in Cancer Drug Development
Waaijer, S. J. H., Kok, I. C., Eisses, B., Schroder, C. P., Jalving, M., Brouwers, A. H., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188045 · Cited by 73
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le, T., & Gerber, D. E. (2019) · Cancers · doi:10.3390/cancers11030366 · Cited by 75
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Tateo, V., Marchese, P. V., Mollica, V., Massari, F., Kurzrock, R., & Adashek, J. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040614 · Cited by 74
Nishio, M., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Tanaka, T., Kuriki, H., Zeaiter, A. H., & Tamura, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.015 · Cited by 73
Self-citationCho, B. C., Obermannova, R. L., Bearz, A., McKeage, M. J., Kim, D.-W., Batra, U., Borra, G., Orlov, S., Kim, S.-W., Geater, S. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.002 · Cited by 72
Self-citationCurrent and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71
Targeting ALK Rearrangements in NSCLC: Current State of the Art
Peng, L., Zhu, L., Sun, Y., Stebbing, J., Selvaggi, G., Zhang, Y., & Yu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863461 · Cited by 71
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Nishio, M., Yoshida, T., Kumagai, T., Hida, T., Toyozawa, R., Shimokawaji, T., Goto, K., Nakagawa, K., Ohe, Y., Seto, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.004 · Cited by 70
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
He, Q., Zhao, X., Wu, D., Jia, S., Liu, C., Cheng, Z., Huang, F., Chen, Y., Lu, T., & Lü, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115741 · Cited by 71
Ramalingam, S. S., Dahlberg, S. E., Belani, C. P., Saltzman, J. N., Pennell, N. A., Nambudiri, G. S., McCann, J., Winegarden, J. D., Kassem, M. A., Mohamed, M. K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01006 · Cited by 70
Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5110 · Cited by 69
EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
Elshatlawy, M., Sampson, J., Clarke, K., & Bayliss, R. W. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13446 · Cited by 74
Routman, D. M., Bian, S. X., Diao, K., Liu, J. L., Cheng, Y., Ye, J. C., Zada, G., & Chang, E. L. (2018) · Cancer Medicine · doi:10.1002/cam4.1352 · Cited by 70
Zhu, V. W., Lin, Y.-T., Kim, D., Loong, H. H.-F., Nagasaka, M., To, H., Ang, Y. L. E., Ock, C.-Y., Tchekmedyian, N., Ou, S. I., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.019 · Cited by 70
Self-citationAbate, R. E., Frezzetti, D., Maiello, M. R., Gallo, M., Camerlingo, R., Luca, A. D., Cecio, R. D., Morabito, A., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12123804 · Cited by 69
Dziadziuszko, R., Mok, T. S. K., Peters, S., Han, J., Alatorre-Alexander, J., Leighl, N. B., Sriuranpong, V., Pérol, M., de Castro, G., Nadal, E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.008 · Cited by 66
Self-citationA systematic review of targeted agents for non-small cell lung cancer
Vestergaard, H. H., Christensen, M. R., & Lassen, U. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1404634 · Cited by 66
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
Katayama, R. (2018) · Cancer Science · doi:10.1111/cas.13504 · Cited by 66
Jahanzeb, M., Lin, H. M., Pan, X., Yin, Y., Baumann, P., & Langer, C. J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.08.003 · Cited by 65
Leonetti, A., Minari, R., Boni, L., Gnetti, L., Verzè, M., Ventura, L., Musini, L., Tognetto, M., & Tiseo, M. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.02.014 · Cited by 65
Pellegrino, B., Facchinetti, F., Bordi, P., Silva, M., Gnetti, L., & Tiseo, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.008 · Cited by 65
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
Nacchio, M., Sgariglia, R., Gristina, V., Pisapia, P., Pepe, F., Luca, C. D., Migliatico, I., Clery, E., Greco, L., Vigliar, E., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.19 · Cited by 66
Systemic therapy for brain metastases
Rick, J. W., Shahin, M. N., Chandra, A., Ore, C. L. D., Yue, J. K., Nguyen, A. T., Yagnik, G., Sagar, S., Arfaie, S., & Aghi, M. K. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.012 · Cited by 64
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Davies, J., Martinec, M., Delmar, P., Coudert, M., Bordogna, W., Golding, S., Martina, R., & Crane, G. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0032 · Cited by 63
Self-citationRisk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study
Roopkumar, J., Poudel, S. K., Gervaso, L., Reddy, C. A., Velcheti, V., Pennell, N. A., McCrae, K. R., & Khorana, A. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15215 · Cited by 65
Omar, N. E., Soliman, A. I. F., Eshra, M. R., Saeed, T., Hamad, A., & Abou‐Ali, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100315 · Cited by 63
Heigener, D. F., & Reck, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_4 · Cited by 64
Pan, K., Concannon, K., Li, J., Zhang, J., Heymach, J. V., & Le, X. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00808-4 · Cited by 65
Ulahannan, D., Khalifa, J., Finn, C. F., & Lee, S. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx481 · Cited by 63
Lin, J. J., Horan, J. C., Tangpeerachaikul, A., Swalduz, A., Valdivia, A., Johnson, M. L., Besse, B., Camidge, D. R., Fujino, T., Yoda, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0231 · Cited by 64
Self-citationLung Cancer: Targeted Therapy in 2025
Bouchard, N., & Daaboul, N. (2025) · Current Oncology · doi:10.3390/curroncol32030146 · Cited by 64
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 64
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
Hou, H., Sun, D., Liu, K., Jiang, M., Liu, D., Zhu, J., Zhou, N., Cong, J., & Zhang, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s190098 · Cited by 63
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 62
Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria
Obi, C. D., Bhuiyan, T., Dailey, H. A., & Medlock, A. E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.894591 · Cited by 65
Maciag, A. E., Stice, J. P., Wang, B., Sharma, A. K., Chan, A. H., Lin, K., Singh, D., Dyba, M. D., Yang, Y., Setoodeh, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0840 · Cited by 62
Reed, M. L., Rosales, A.-L. S., Chioda, M. D., Parker, L., Devgan, G., & Kettle, J. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01365-3 · Cited by 60
Palmero, R., Taus, Á., Viteri, S., Majem, M., Carcereny, E., Garde, J., Felip, E., Nadal, E., Malfettone, A., Sampayo-Cordero, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00241 · Cited by 60
Self-citationOcular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 60
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 65
Multiscale profiling of protease activity in cancer
Amini, A. P., Kirkpatrick, J. D., Wang, C. S., Jaeger, A. M., Su, S., Naranjo, S., Zhong, Q., Cabana, C. M., Jacks, T., & Bhatia, S. N. (2022) · Nature Communications · doi:10.1038/s41467-022-32988-5 · Cited by 60
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Self-citationPacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60
Self-citationImaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Enright, T. L., Witt, J. S., Burr, A. R., Yadav, P., Leal, T. A. B., & Baschnagel, A. M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.014 · Cited by 60
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Hofman, P. M. (2017) · Cancers · doi:10.3390/cancers9080107 · Cited by 61
Schödel, P., Jünger, S. T., Wittersheim, M., Reinhardt, H. C., Schmidt, N. O., Goldbrunner, R., Proescholdt, M. A., & Grau, S. (2020) · Cancer Medicine · doi:10.1002/cam4.3402 · Cited by 62
Petrelli, F., Stefani, A. D., Trevisan, F., Parati, M. C., Inno, A., Merelli, B., Ghidini, M., Bruschieri, L., Vitali, E., Cabiddu, M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102830 · Cited by 59
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Cameron, L. B., Hitchen, N., Chandran, E. B. A., Morris, T., Manser, R., Solomon, B., & Jordan, V. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013453.pub2 · Cited by 58
Review of Current Principles of the Diagnosis and Management of Brain Metastases
Brenner, A. W., & Patel, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857622 · Cited by 58
Metadata
- Authors
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 829-838
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624310346
- Cited by
- 2,527
- References
- 14
- Citations by year
- 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
- FWCI
- 218.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ariad Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Clovis Oncology
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Ignyta
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
